16:22:19 EDT Tue 16 Apr 2024
Enter Symbol
or Name
USA
CA



Imagin Medical Inc
Symbol IME
Shares Issued 90,055,272
Close 2018-01-15 C$ 0.40
Market Cap C$ 36,022,109
Recent Sedar Documents

Imagin Medical appoints Vacha as CFO

2018-01-15 12:10 ET - News Release

Mr. Jim Hutchens reports

IMAGIN MEDICAL RECRUITS SENIOR HEALTHCARE INDUSTYRY CFO

Imagin Medical Inc. has hired John Vacha as the company's new chief financial officer.

Mr. Vacha is a licensed CPA in Massachusetts, holds an MBA and an MS in accounting from Northeastern University in Boston, Mass., and has 20 years of experience in the health care industry. Most recently, Mr. Vacha served as president, chief executive officer and board member of Intact Medical Corp. for seven years before it was acquired by Medtronic in 2017. Previously, he served as vice-president, CFO and treasurer of the company. Mr. Vacha also served as senior consultant at Deloitte & Touche LLP, where his clients included closely held high-tech manufacturing start-up companies, as well as large retail and manufacturing corporations. Mr. Vacha also serves as a member of the board of directors at the South Boston Health Center and holds two patents in electrosurgical instrumentation.

This addition supports one of the company's goals to establish a United States based medical device company in the Boston area. New England is considered one of the medical technology hubs in the U.S. and offers relevant services to a medical technology company like Imagin Medical.

Jorge Avelino, Imagin's founding CFO, will continue to maintain the company's Vancouver office and relationships as he transitions into his retirement plans. He will oversee Imagin's interactions with the Canadian Securities Exchange (CSE) and regulatory authorities, as well as continue to manage corporate matters with the company's bank, legal counsel and auditors.

About Imagin Medical Inc.

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.